Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)

Liakos, C.; Papadopoulos, Dimitrios; Sanidas, Elias; Markou, M.; Hatziagelaki, Erifili; Grassos, Charalampos; Velliou, Maria; Barbetseas, John

doi:10.1007/s40256-020-00423-z

Cited by 33 publications

(27 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some evidence suggested that GLP-1 agonists and DPP-4i can influence the hemodynamic state and modify BP [55][56][57]. We have reviewed all possible mechanisms associated with this class of agents and hemodynamics in the following sections (Table 1).…”

Section: Possible Links Between Glp-1ra and Ddp-4i And Blood Pressurementioning

confidence: 99%

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

Yaribeygi

Farrokhi

Abdalla

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of newly introduced antidiabetic medications that potentially lower blood glucose by several molecular pathways. DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby increasing the activity levels of GLP-1, leading to more glucose-induced insulin release from islet β-cells and suppression of glucagon release. Most patients with diabetes have concurrent hypertension and cardiovascular disorder. If antihyperglycemic agents can attenuate the risk of hypertension and cardiovascular disease, they will amplify their overall beneficial effects. There is conflicting evidence on the cardiovascular benefits of GLP-1R induction in laboratory studies and clinical trials. In this study, we have reviewed the main molecular mechanisms by which GLP-1R induction may modulate the cardiovascular function and the results of cardiovascular outcome clinical trials.

show abstract

Section: Possible Links Between Glp-1ra and Ddp-4i And Blood Pressurementioning

confidence: 99%

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

Yaribeygi

Farrokhi

Abdalla

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…[4] Among them, DPP-4 has recently become a hot research topic in the development of hypoglycaemic drugs which was used for the treatment of type 2 diabetes, which can inhibit the inactivation of glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), improving the levels of endogenous GLP-1 and promoting the release of insulin from pancreatic β cells by GIP and it can also inhibit the secretion of glucagon from pancreatic α cells, thereby increasing the insulin levels and lowering the blood sugar. [5] At present, there are 12 kinds of DPP-4 inhibitors that have entered the market, and 4 drugs are in the clinical research stage and many new small DPP-4 inhibitors are in the preclinical research stage. [6] The biggest advantage of antidiabetic drugs targeting DPP-4 is not easy to induce hypoglycemia and weight gain.…”

Section: Introductionmentioning

confidence: 99%

Research Progress on the Synthesis and Structure-Activity Relationship of Five Hypoglycemic Active Heterocycles Based on Dipeptidyl Peptidase 4 (DPP-4) Target Design

Kong¹,

Yang²,

Zhou³

et al. 2022

Chinese Journal of Organic Chemistry

View full text Add to dashboard Cite

Recently, diabetes has gradually become a main life-threatening disease in China. Drug targets for the treatment of diabetes mainly include dipeptidyl peptidase 4 (DPP-4), adenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma (PPARγ) receptor and so on, in which targeted drug research targeting DPP-4 is a hot spot in recent years. DPP-4 inhibitor is a drug for the treatment of type 2 diabetes, and its biggest advantage is that it is not easy to induce hypoglycemia and increase weight. It is reported that the currently available DPP-4 targeted drugs can cause adverse reactions, such as pancreatitis and hypersensitivity. Therefore, it is worth further studying to continue to develop new hypoglycemic drugs for DPP-4 inhibitors to avoid adverse reactions. According to the systematic literature review, the potential heterocyclic structures with hypoglycemic activity are summarized and through computer molecular simulation docking, five kinds of heterocyclic structures with high hypoglycemic activity and easy synthesis are finally screened out based on DPP-4 target design. The synthesis routes and structure-activity relationships are summarized and analyzed, which provides a research basis for the development of safe, efficient and novel hypoglycemic drugs for DPP-4 inhibitors in the future. Keywords diabetes; dipeptidyl peptidase 4 (DPP-4) inhibitor; molecular docking; synthesis methods; structure-activity relationship

show abstract

“…Dipeptidyl peptidase-4 (DPP-4) is a kind of serine proteinase mainly expressed in small intestine, liver, kidney, pancreas and spleen. In vivo, it can resolve GLP-1, resulting in the decreasing of insulin secretion and the occurrence of diabetes [1][2][3]. DPP-4 has become a hot target in the development of hypoglycemic drugs recently.…”

Section: Introductionmentioning

confidence: 99%

Exploring of hypoglycemic mechanism of a Chinese Medicine Xiao-Ke-An based on target dipeptidyl peptidase-4：a molecular docking and molecular dynamics study

Wang¹,

Zhen²,

Tong³

et al. 2021

Preprint

View full text Add to dashboard Cite

Xiao-Ke-An, a traditional Chinese medicine formula against diabetes in China, is reported inhibitory activity on Dipeptidyl peptidase-4 (DPP-4). However, its molecular mechanism is still unclear due to the complexity of its components. In this study, a combination of molecular docking, molecular dynamics (MD) and molecular mechanics/Poisson Boltzmann surface area (MM-PBSA) method was conducted. The results show that multiple components of Xiao-Ke-An can take effect on DPP-4 together, which could be the part of the hypoglycemic mechanism of Xiao-Ke-An. Of the eight selected compounds, MOL003714 shows the highest activity for inhibiting DPP-4 with the binding free energy of -44.14 kcal·mol− 1 via binding to the S2 and S'1 subsites of DPP-4, which could be a potent inhibitor for DPP-4. This study provided theoretical basis for the discovery and modification of natural DPP-4 inhibitors and the deeply insight into Xiao-Ke-An.

show abstract

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)

Cited by 33 publications

References 83 publications

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes

Research Progress on the Synthesis and Structure-Activity Relationship of Five Hypoglycemic Active Heterocycles Based on Dipeptidyl Peptidase 4 (DPP-4) Target Design

Exploring of hypoglycemic mechanism of a Chinese Medicine Xiao-Ke-An based on target dipeptidyl peptidase-4：a molecular docking and molecular dynamics study

Contact Info

Product

Resources

About